As of 2024-12-12, the Relative Valuation of Newbury Pharmaceuticals AB (NEWBRY.ST) is - SEK. This relative valuation is based on P/E multiples. With the latest stock price at 3.62 SEK, the upside of Newbury Pharmaceuticals AB based on Relative Valuation is -.
The range of the Relative Valuation is - SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | P/E |